Table 2.
The table summarizes the data obtained after inoculation with the different patient-derived homogenates (left) or PMCA-amplified αSYN assemblies (right) in association with human αSYN expression
| rAAV-αSYN + HOMOGENATES | rAAV-αSYN + PMCA | |||||||
|---|---|---|---|---|---|---|---|---|
| CTR | PD | MSA | DLB | CTR | PD | MSA | DLB | |
| Motor deficits | + | − | ||||||
| DA degeneration SN | + | + | + | + | ||||
| Stiatal nerve loss | + | − | ||||||
| αSYN pathology SN | + | − | ||||||
| αSYN spreading | + | ++ | − | |||||
| Immune response | + | ++ | − | |||||
The following parameters are included: motor deficits, dopaminergic neuronal cell loss in the SN, striatal nerve loss, αSYN pathology in the SN, spreading of αSYN pathology and immune response. The scoring system ranges from not/mildly present (−) to strongly present (++)
αSYN α-synuclein, DA dopaminergic, rAAV-αSYN recombinant adeno-associated viral vector expressing αSYN, SN substantia nigra